arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

GILEAD SCIENCES, INC.

GILD
$167.62 ▼ -6.83 (-3.92%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
76 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Excellent
Bullish
auto_awesome

Analytical Summary

GILEAD SCIENCES, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $208.2B
Dividend Yield 0.49%
Revenue Growth 6.8% ↘
Op. Margin 41.7% ↗
ROIC 7.0% ↗
FCF / Share $3.86 ↗
Trailing P/E 85.5x
Price / Book 16.0x
FCF Yield 2.3%
Debt / Equity 2.01
info Valuation on last close. End-of-day price, Nov 5, 2026.

76-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.30B
↑ +6.8% —
Net Income Profit after all expenses
$2.43B
↓ -20.4% —
Operating Margin Operating profit as % of sales
41.7%
↑ +131.3% 89th
FCF / Share Free cash flow per share
$3.86
↑ +39.9% —
Long-Term Debt Long-term obligations
$26.23B
— -0.1% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
91
Returns ↑
95
Financial Health ↓
54
Cash Quality ↓
70

Dividend History

Dividend / share · sourced from SEC filings
$3.16 Latest / share
+2.6% YoY

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 76 quarters